SCHEMBL1328282

SCHEMBL1328282

CCc1cccc(CC)c1-c1cc(OC(C)C)c(COc2cc(C(=O)N3CCN(C)CC3)ccc2C)c(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
NPC1 O15118 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
AVPR2 P30518 1/20 0.38
AVPR1A P37288 1/20 0.38
TTK P33981 3/20 0.38
AURKA O14965 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
KDM4E B2RXH2 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
HPGD P15428 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1327126 0.94 MEN1 (0.43) LRRK2SMN1; SMN2ALDH1A1NPC1GAA
SCHEMBL1328960 0.91 LRRK2 (0.45) LRRK2SMN1; SMN2ALDH1A1NPC1GAA
SCHEMBL1329169 0.84 MEN1 (0.39) ALDH1A1RAB9AC5AR1
SCHEMBL1328110 0.83 C5AR1 (0.36) LRRK2RAB9ATTKCYP3A4USP2
SCHEMBL1327921 0.83 C5AR1 (0.37) ALDH1A1KDM4EHPGDC5AR1
SCHEMBL1328918 0.82 ALDH1A1 (0.40) LRRK2ALDH1A1HPGDC5AR1
SCHEMBL2142265 0.82 C5AR1 (0.41) ALDH1A1HPGDTSHRC5AR1
SCHEMBL1327872 0.81 C5AR1 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9ACYP2C9
SCHEMBL1327146 0.79 C5AR1 (0.42) SMN1; SMN2ALDH1A1C5AR1
SCHEMBL1327245 0.79 SCN9A (0.39) SMN1; SMN2ALDH1A1NPC1GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES HUTCHINSON ALAN J (US) 2011-11-17 US disclosed
US-7863454-B2 3-substituted-6-aryl pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2011-01-04 US disclosed
US-20090176980-A1 3-Substituted-6-Aryl Pyridines NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2009-07-09 US disclosed
US-7342115-B2 Binding antagonist and arylpyridine for antiinflammatory agents, cardiovascular disorders and antagonist or agonist and for immunology NEUROGEN CORPORATION (US) 2008-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281837-A1 3-SUBSTITUTED-6-ARYL PYRIDINES C3AR1, C5AR1, C5AR2 LRRK2 1127/4885SMN1; SMN2 4559/4885ALDH1A1 1966/4885
US-20090176980-A1 3-Substituted-6-Aryl Pyridines C3AR1, C5AR1, C5AR2 LRRK2 1127/4885SMN1; SMN2 4559/4885ALDH1A1 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.